Try our Advanced Search for more refined results
Sandoz Inc. v. Amgen Inc. et al
Case Number:
3:13-cv-02904
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
November 13, 2013
1st Biosimilars Act Ruling May Limit Patent Challenges
The ability of biosimilars makers to make early challenges to biologic drug patents may be curtailed by a Tuesday ruling throwing out Sandoz Inc.'s suit to invalidate patents for Amgen Inc.'s biologic arthritis drug Enbrel, the first time a judge has interpreted the litigation provisions of the Biosimilars Act.
-
June 26, 2013
Sandoz Fights Amgen Enbrel Patent
Amgen Inc. and Hoffman-La Roche Inc. were struck with a California federal lawsuit Tuesday from Sandoz Inc. that says a generic form of arthritis drug Enbrel is not infringing two patents and a delay in the patents' issuance renders them invalid.